Target intelligence / Profile preview

E3 ubiquitin-protein ligase SHPRH (SHPRH)

Target
SHPRH
Molecular classification
Enzyme, E3 ubiquitin ligase, DNA helicase, DNA repair protein, Transcription factor (motif-containing)
01

Overview

E3 ubiquitin-protein ligase SHPRH (SHPRH) is a multifunctional protein characterized by DNA helicase, PHD, and RING finger domains, and is ubiquitously expressed in human tissues[2][3][4]. It acts predominantly as a nucleosome-stimulated ATPase and E3 ubiquitin ligase, orchestrating DNA repair by promoting non-canonical polyubiquitination of PCNA in response to genotoxic stress[2][7]. SHPRH is a functional homolog of yeast RAD5 and is implicated in chromatin remodeling and transcriptional regulation through its domain architecture[2][3][5]. Dysregulation and reduced expression of SHPRH have been observed in cancers such as glioblastoma, where it acts as a tumor suppressor by stabilizing its own protein levels and regulating cell proliferation via ubiquitination pathways[1][2]. SHPRH gene variations are associated with inherited DNA repair syndromes including xeroderma pigmentosum and Fanconi anemia[2][5].

Other names
SNF2 histone linker PHD RING helicaseKIAA2023FLJ90837bA545I5.2RING-type E3 ubiquitin transferase SHPRHRAD52610103K11Rik
02

Mechanism of action

Drugs targeting this protein would theoretically modulate DNA repair via influencing ubiquitination of PCNA and related DNA damage response; currently, no specific drugs are listed in search results[1][2][5].

03

Biological functions

DNA repairProtein ubiquitinationHelicase activity (ATP-dependent)Regulation of cell proliferationTumor suppressionChromatin remodeling
04

Disease associations

Cancer (including glioblastoma, brain neoplasms)Xeroderma pigmentosum, variant typeFanconi anemia
05

Safety considerations

Potential safety concerns include unwanted modulation of DNA repair or cell proliferation, with risks for carcinogenesis or tissue dysfunction if targeted inappropriately; therapeutic challenge lies in selective modulation without affecting normal DNA repair[1][2].
06

Biomarkers

Downregulation in glioblastoma and certain other cancersExpression levels for patient selection or pharmacodynamic monitoring in brain tumors[1]

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase SHPRH (SHPRH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase SHPRH (SHPRH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call